Tibet Rhodiola Pharmaceutical Publishes 1H 2020 Financials
Tibet Rhodiola Pharmaceutical (600211:SH) disclosed the 2020 H1 financial report with semi-annual revenue of CNY 629 million, net profits of CNY 220 million and EPS of CNY 1.1. The company currently has 500 employees and realized a revenue of CNY 1256 million in 2019.
Founded in 1999, it is the first high-tech pharmaceutical company in Tibet Autonomous Region. The company covers biopharmaceutical, Tibetan medicines, Chinese herbology and chemical drugs. Now it has built a national selling channel and has extended the business over 40 countries.